p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis

International Journal of Cancer

Volumn 74, Issue 5, 1997, Pages 529-534

  Jiang, Ming ^a   Shao, Zhi Ming ^a   Wu, Jun ^a   Lu, Jing Song ^a   Yu, Li Ming ^a   Yuan, Jian Da ^a   Han, Qi Xia ^a   Shen, Zhen Zhou ^a   Fontana, Joseph A ^b  

^a FUDAN UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; NUCLEAR PROTEIN; PROTEIN MDM2; PROTEIN P21; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION;

ADULT; AGED; BREAST NEOPLASMS; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; NUCLEAR PROTEINS; PHENOTYPE; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTORS, ESTROGEN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030667191     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19971021)74:5<529::AID-IJC9>3.0.CO;2-5     Document Type: Article

References (33)

1. WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen-receptor status, MIB1 expression. p53 gene and protein alterations and relapse-free survival. Brit. J. Cancer, 74, 208-215 (1996a).
2. WAF1 and p53 immunohistochemical expression in breast carcinoma may predict therapeutic response to adjuvant treatment. Europ. J. Cancer, 32, 2182-2183 (1996b).
3. BUESO-RAMOS, C., MANSHOURI, T., HAIDAR, M., YANG, Y., McCOWN, P., ORDONEZ, N., GLASSMAN, A., SNEIGE, N. and ALBITAR, M., Abnormal expression of MDM-2 in breast carcinoma. Breast Cancer Res. Treat., 37, 179-188 (1996).
4. BUKHOLM, I.K., NESLAND, J.M., KARLSEN, R., JACOBSEN, U. and BORRESEN, A.L., Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. J. Pathol., 181, 140-145 (1997).
5. CHEN, C.Y., OLINER, J.D., ZHAN, Q., FORNACE A.J. JR., VOGELSTETN, B. and KASTAN, M.B., Interaction between p53 and MDM2 in a mammalian cell-cycle checkpoint pathway. Proc. nat. Acad. Sci. (Wash.), 91, 2684-2688 (1994).
6. CHEN, Y.-Q., CIPRIANO, S.C., ARENKIEL, J.M. and MILLER, F.R., Tumor suppression by p21WAF1. Cancer Res., 55, 4536-4539 (1995).
7. DATTO, M.B., LI, Y. PANUS, J.F., HOWE, D.J., XIONG, Y. and WANG, X.F., Transforming growth factor β induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc. nat. Acad. Sci. (Wash.), 92, 5545-5549 (1995).
8. DOGLIONI, C., PELOSIO, P., LAURINO, L., MACRI, E., MEGGIOLARO, E., FAVRETTI, F. and BARBARESCHI, M., p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. J. Pathol., 179, 248-253 (1996).
9. EL-DEIRY, W.S., TOKINO, T., VELCULESCU, V.E., LEVY, D.B., PARSONS, R., TRENT, L.M., LIN, D., MERCER, W.E., KINZLER, K.W. and VOGELSTEIN, B., WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825 (1993).
10. EL-DEIRY, W.S., TOKINO, T. and WALDMAN, T., Topological control of p21WAF1/CIP1 expression in normal and neoplastic tissues. Cancer Res., 55, 2910-2919 (1995).
11. ELSTON, C.W. and ELLIS, I.O., Pathological prognostic factors in breast cancer, the value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology, 19, 403-410 (1991).
12. ENCOH, T. and NORBURY, C., Cellular responses to DNA damage: cell-cycle checkpoints, apoptosis and the roles of p53 and ATM. Trendy biol. Sci., 20, 426-430 (1995).
13. HALEY, O., NOVITCH, B.C., SPICER, D.B., SKAPEK, S.X., RHEE, J., HANNON, G.J., BEACH, D. and LASSAR, A.B., Correlation of terminal cell-cycle arrest of skeletal muscle with induction of p21 by MyoD. Science, 267, 1018-1024 (1995).
14. HARTWELL, L. and KASTAN, M.B., Cell-cycle control and cancer. Science, 266, 1820-1828 (1994).
15. HUNT, T. and NASMYTH, K., Dams and sluices. Nature (Lond.), 366, 634-635 (1993).
16. JIANG, H., LIN, J., SU, Z.Z., COLLART, F.R., HUBERMAN, E. and FISHER, P.B., Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53. Oncogene, 9, 3397-3406 (1994).
17. JOHNSON, E.A., DAVIDSON, A.G., HOSTETTER, R.B., COOK, L.L., THOMAS, E.M. and QUINLAN, D.C., The expression of WAF-1 in node-negative infiltrating ductal breast carcinoma. Proc. Amer. Ass. Cancer Res., 37, 569a (1996).
18. KITE, T.E., SHAO, Z-M., SUGG, N.K., LONG, R.T., RUSSEL, G.B. and CASE, L.D., Cathepsin-D as a prognostic indicator for node-negative breast-cancer patients using both immunoassays and enzymatic assays. Cancer Res., 50, 4901-4909 (1992).
19. LI, X.S., RISHI, A.K., SHAO, Z.M., DAWSON, M.I., JONG, L., SHROOT, B., REICHERT, U., ORDONEZ, J. and FONTANA, J.A., Post-transcriptional regulation of p21 WAF1/CIP1 expression in human breast-carcinoma cells. Cancer Res., 56, 5055-5062 (1996).
20. LI, Y., LAURENT-PUIG, P., SALMON, R.J., THOMAS, G. and HAMELIN, R., Polymorphism and probable lack of mutation in the WAf1/CIP1 gene in colorectal cancer. Oncogene, 10, 599-601 (1995).
21. MARCHETTI, A., BUTTITTA, F., GIRLANDOS, DALLA PALMA, P., PELLEGRINI, S., FINA, P., DOGLIONI, C., BEVILACQUA, G. and BARBARESCHI, M., mdm2-gene alteration and mdm2 protein expression in breast carcinomas. J. Pathol., 175, 31-38 (1995a).
22. MARCHETTI, A., BUTTITTA, F., PELLEGRINI, S., LORI, A., BERTACCA, G. and BEVILACQUA, G., Absence of somatic mutations in the coding region of the WAF1/CIP1 gene in human breast, lung and ovarian carcinoma: a polymorphism at codon 31. Int. J. Oncol., 6, 187-189 (1995b).
23. MARCHETTI, A., DOGLIONI, C. and BARBARESCHI, M., p21 mRNA and protein expression in non-small-cell lung cancer: evidence of p53-independent expression and association with tumoral differentiation. Oncogene, 12, 1319-1324 (1996).
24. MICHIELI, P., CHEDID, M., LIN, D., PIERCE, J.H., MERCER, W.E. and GIVOL, D., Induction of WAF1/CIP1 by p53-independent pathway. Cancer Res., 54, 3391-3395 (1994).
25. OLINER, J.D., KINZLER, K.W. and METLZER, P.S., Amplification of gene encoding 1 p53-associated protein in human sarcomas. Nature (Lond.), 358, 80-83 (1992).
26. OLINER, J.D., PIETENPOL, J.A., THIAGALINGAM, S., GYURIS, J., KINZLER, W.K. and VOGELSTEIN, B., Oncoprotein MDM2 conceals the activation domain of suppressor p53. Nature (Lond.), 362, 857-860 (1993).
27. 0 arrest and apoptosis induced by a novel retinoid in human breast-cancer cells. Oncogene, 11, 493-504 (1995).
28. SHEIKH, M.S., SHAO, Z-M., HUSSAIN, H. and FONTANA, J.A., The p53-binding protein MDM2 is differentially expressed in human breast carcinoma. Cancer Res., 53, 3226-3228 (1993).
29. WAF-1 in human cutaneous squamous-cell carcinoma. Amer. J. Pathol., 149, 1139-1146 (1996).
30. XIONG, Y., HANNON, G.I., ZHANG, H., CASSO, D., KOBAYASHI, R. and BEACH, D., p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366, 701-707 (1993).
31. ZAMBETTI, G.P. and LEVINE, A.J., A comparison of the biological activities of wild-type and mutant p53. FASEB J., 7, 855-865 (1993).
32. ZHANG, W., GRASSO, L., McCLAIN, C.D., CAMBREL, A.M., CHA, Y., TRAVALI, S., DEISSEROTH, A.B. and MERCER, W.E., p53-independent induction of WAF1/CIP1 in human leukemia cells is correlated with growth arrest accompanying monocyte/macrophage differentiation. Cancer Res., 55, 668-674 (1995a).
33. ZHANG, W., KORNBLAU, S.M., KOBAYASHI, T., GAMBEL, A., CLAXTON, D. and DEISSEROTH, A.B., High levels of constitutive WAF1/CIP1 protein are associated with chemoresistance in acute myelogenous leukemia. Clin. Cancer Res., 1, 1051-1057 (1995b).